Galmed Pharmaceuticals Amends Articles of Association Following Shareholder Approval

Galmed Pharmaceuticals ( (GLMD) ) has issued an update.

On August 15, 2025, Galmed Pharmaceuticals held a Special General Meeting of Shareholders where a proposal was approved in accordance with Israeli Companies Law. This approval led to the amendment and restatement of the company’s articles of association, which could have implications for the company’s governance and operational flexibility.

Spark’s Take on GLMD Stock

According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.

Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.

To see Spark’s full report on GLMD stock, click here.

More about Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development of innovative solutions for liver diseases. The company primarily engages in the research and development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-related conditions.

Average Trading Volume: 316,953

Technical Sentiment Signal: Sell

Current Market Cap: $3.34M

For a thorough assessment of GLMD stock, go to TipRanks’ Stock Analysis page.